大成食品(03999.HK)與蘇華建設訂立建設協議
格隆匯1月13日丨大成食品(03999.HK)公吿,於招標程序後,於2022年1月13日,蚌埠大成(公司間接全資附屬公司)與承建商蘇華建設集團有限公司(中標方)訂立建設協議,據此,承建商將以代價人民幣8200萬元向蚌埠大成提供工廠廠房及配套建築、設施建設服務。
承建商須負責蚌埠大成位於中國安徽省蚌埠市固鎮縣、佔地面積約為91.57畝的工廠廠房及配套建築、設施建設工程。
集團正緊張有序推進在安徽省蚌埠市新建廠房項目。該工程是本集團食品一條龍產業鏈規模擴張的重要一環,符合集團的長期發展策略。項目建成將有助於為本集團食品事業長遠發展建立穩定而高效的供應鏈系統,進一步鞏固本集團在中國長三角地區的市場地位。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.